[go: up one dir, main page]

GB201308658D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201308658D0
GB201308658D0 GBGB1308658.2A GB201308658A GB201308658D0 GB 201308658 D0 GB201308658 D0 GB 201308658D0 GB 201308658 A GB201308658 A GB 201308658A GB 201308658 D0 GB201308658 D0 GB 201308658D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1308658.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1308658.2A priority Critical patent/GB201308658D0/en
Publication of GB201308658D0 publication Critical patent/GB201308658D0/en
Priority to PCT/GB2014/051469 priority patent/WO2014184545A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1308658.2A 2013-05-14 2013-05-14 Antibodies Ceased GB201308658D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1308658.2A GB201308658D0 (en) 2013-05-14 2013-05-14 Antibodies
PCT/GB2014/051469 WO2014184545A2 (en) 2013-05-14 2014-05-14 Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1308658.2A GB201308658D0 (en) 2013-05-14 2013-05-14 Antibodies

Publications (1)

Publication Number Publication Date
GB201308658D0 true GB201308658D0 (en) 2013-06-26

Family

ID=48700766

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1308658.2A Ceased GB201308658D0 (en) 2013-05-14 2013-05-14 Antibodies

Country Status (2)

Country Link
GB (1) GB201308658D0 (en)
WO (1) WO2014184545A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938063A (en) * 2018-09-21 2020-03-31 东进世美肯株式会社 Novel compound for cap layer and organic light-emitting device comprising the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40662B1 (en) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Antibodies against tigit
KR20180021833A (en) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 Antibodies to CD40 with enhanced agonist activity
US10894835B2 (en) 2016-03-04 2021-01-19 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
CN113201071A (en) 2017-03-28 2021-08-03 礼进生物医药科技（上海）有限公司 Therapeutic agents and methods for enhancing immune response in tumor microenvironment
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
JP7257335B2 (en) 2017-05-25 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー Antagonistic CD40 monoclonal antibodies and uses thereof
CN111788227B (en) 2017-12-27 2025-02-25 百时美施贵宝公司 Anti-CD40 antibodies and uses thereof
CN110151987B (en) * 2018-02-11 2023-10-13 汕头大学医学院 Use of symmetrical IgG and its composition in preparing drugs for treating and preventing tumors
AR117091A1 (en) 2018-11-19 2021-07-07 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES
WO2020207470A1 (en) 2019-04-10 2020-10-15 南开大学 Anti-cd40 antibody and use thereof
AU2021231997A1 (en) * 2020-03-05 2022-10-20 Momenta Pharmaceuticals, Inc. Methods of making hyper-sialylated immunoglobulin
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US20250186520A1 (en) * 2020-10-26 2025-06-12 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
EP2036985A1 (en) * 2002-04-09 2009-03-18 Nationwide Children's Hospital, Inc. Antibody gene transfer and recombinant AAV therefor
CN103172731A (en) * 2004-07-15 2013-06-26 赞科股份有限公司 Optimized Fc variants
US20070023129A1 (en) 2005-07-29 2007-02-01 Stieler David C Method of coupling polymeric tubing to polymeric coated metal tubing
PT2853545T (en) * 2008-09-17 2016-08-26 Xencor Inc Antibody specific for ige
JP2014517846A (en) * 2011-05-25 2014-07-24 メルク・シャープ・アンド・ドーム・コーポレーション Process for producing Fc-containing polypeptides having improved properties

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938063A (en) * 2018-09-21 2020-03-31 东进世美肯株式会社 Novel compound for cap layer and organic light-emitting device comprising the same

Also Published As

Publication number Publication date
WO2014184545A3 (en) 2015-02-19
WO2014184545A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
ZA201808451B (en) Anti-fcrh5 antibodies
GB201322583D0 (en) Antibodies
SG11201509361TA (en) Novel antibodies
ZA201603218B (en) Afucosylated anti-fgfr2iiib antibodies
ZA201601437B (en) Antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti-ccl17 antibodies
IL241410A0 (en) Anti-cd52 antibodies
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)